The identification of elevated FGF-23 levels in FAM20A-related ERS with severe nephrolithiasis and hypophosphatemia raises the question of the interest of burosumab as targeted therapy. The gene discussed is FGF23; the disease is amelogenesis imperfecta type 1G.